GlassScriptPhysician profile
Michael K Greenberg
NPI 1932192150
$3,691.84
in general payments reported to CMS, 2019-2025
36 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $366 · 2021: $126 · 2022: $475 · 2023: $332 · 2024: $331 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $679.53 | 2019-2024 | |
| Biogen, INC. | $391.24 | 2019-2025 | Tysabri, Vumerity |
| Alexion Pharmaceuticals, INC. | $218.88 | 2019-2022 | |
| Amgen INC. | $148.71 | 2022-2025 | Uplizna |
| Genzyme Corporation | $145.62 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $143.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $110.08 | 2019-2020 | |
| Emd Serono, INC. | $107.25 | 2019-2020 | |
| Lilly USA, LLC | $90.77 | 2019-2024 | Amyvid, Kisunla |
| Genentech USA, INC. | $90.29 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $89.47 | 2019-2020 | |
| Ucb, INC. | $77.52 | 2019-2020 | |
| Horizon Therapeutics Plc | $76.05 | 2022-2023 | Uplizna |
| Allergan, INC. | $59.58 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $50.74 | 2024 | Nourianz |
| Neurocrine Biosciences, INC. | $41.30 | 2019-2023 | Ingrezza, Ongentys |
| Eisai INC. | $40.28 | 2024 | |
| Amneal Pharmaceuticals LLC | $34.83 | 2019-2022 | |
| Celgene Corporation | $32.76 | 2023-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $31.94 | 2019 | |
| Acorda Therapeutics, INC | $29.66 | 2019 | |
| Averitas Pharma INC. | $29.39 | 2025 | Qutenza |
| Abbott Laboratories | $28.88 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.02 | 2025 | Ponvory |
| Pfizer INC. | $23.66 | 2025 | |
| Tg Therapeutics, INC. | $22.13 | 2024 | |
| Argenx US, INC. | $21.88 | 2022 | |
| Grifols USA, LLC | $18.68 | 2019 | |
| Csl Behring | $18.13 | 2020 | |
| Tanabe Pharma America, INC. | $16.90 | 2019 | |
| Adamas Pharmaceuticals, INC. | $16.62 | 2019 | |
| Lundbeck LLC | $15.71 | 2019 | |
| Neurelis, INC. | $13.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.63 | 2022 | |
| Banner Life Sciences, LLC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.